Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I TrialMartin Hutchings, Michael Dickinson, Franck Morschhauser et al.|Journal of Clinical Oncology|2021Cited by 428
Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin LymphomaMartin Hutchings, Michael Dickinson, Carmelo Carlo‐Stella et al.|Blood|2020Cited by 56
GAIN-(L): Efficacy and biomarker findings of RG7160 (GA201), a novel, dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with first-line cisplatin and pemetrexed in metastatic nonsquamous NSCLC.James Spicer, Luis Paz‐Ares, Ana Montes et al.|Journal of Clinical Oncology|2012Cited by 0